GlassScriptPhysician profile
David A Keen
NPI 1295759512
$4,764.61
in general payments reported to CMS, 2019-2025
30 companies · $533 in 2025
The $533 reported for 2025 was more than what 75% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $352 · 2020: $698 · 2021: $755 · 2022: $586 · 2023: $801 · 2024: $1,039 · 2025: $533.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,374.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,373.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,281.78 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Novo Nordisk INC | $840.54 | 2019-2025 | Ozempic, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $498.48 | 2022-2025 | |
| Glaxosmithkline, LLC. | $392.46 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $333.51 | 2019-2024 | Mounjaro, Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $170.24 | 2019-2022 | |
| Abbvie INC. | $124.66 | 2021 | |
| Amarin Pharma, INC. | $122.11 | 2019-2020 | |
| Amgen INC. | $117.38 | 2023-2024 | Repatha, Otezla |
| Exact Sciences Corporation | $96.43 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $94.00 | 2020-2024 | Jardiance |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $79.31 | 2022-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $76.44 | 2021-2024 | Abilify Asimtufii, Rexulti |
| Pfizer INC. | $66.38 | 2019-2024 | |
| Janssen Pharmaceuticals, INC | $61.66 | 2020-2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Radius Health, INC. | $60.04 | 2023-2025 | Tymlos |
| Allergan, INC. | $54.82 | 2019-2020 | |
| Ucb, INC. | $41.82 | 2025 | Bimzelx |
| Merck Sharp & Dohme LLC | $29.90 | 2020-2021 | |
| Kowa Pharmaceuticals America, INC. | $29.00 | 2022 | |
| Avanir Pharmaceuticals, INC. | $28.43 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $23.98 | 2020-2022 | |
| Almatica Pharma LLC | $20.25 | 2024 | Teriparatide |
| Genentech USA, INC. | $19.70 | 2019 | |
| Paratek Pharmaceuticals, INC. | $19.53 | 2024 | Nuzyra |
| Verona Pharma, INC. | $19.23 | 2025 | Ohtuvayre |
| Teva Pharmaceuticals USA, INC. | $16.99 | 2019 | |
| Supernus Pharmaceuticals, INC. | $16.38 | 2024 | Qelbree |
| Adlon Therapeutics L.P. | $15.12 | 2021 | |
| Nestle Healthcare Nutrition INC. | $14.04 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Keen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.